Weight Loss

From treatment to trend, slimming drug boom sparks misuse concerns

Doctors caution against cosmetic misuse of GLP-1 drugs as cheaper generics boost access, raising risks of unsupervised use and short-term weight-loss trends

Eli Lilly's Mounjaro sales dip as semaglutide generics flood Indian market

Mounjaro sales in March dropped to ₹114 crore ($12.3 million) in March from ₹135 crore a month earlier, Pharmarack data show

Can Ozempic and similar weight loss drugs cause hair loss? Experts explain

Experts explain the science behind hair loss reports, noting that the shedding is usually temporary and linked to how the body responds to rapid weight loss

Centre increases monitoring of weight-loss drugs, flags safety concerns

Regulators have been asked to track adverse events as India tightens oversight on popular obesity drugs amid rising demand and concerns over misuse and misleading promotions

India's 'Mounjaro brides': Weight-loss injections enter pre-wedding prep

Many marriages are still arranged by families, often accompanied by expectations around physical appearance and financial status, which is driving a growing demand for weight-loss solutions

Cheap, accessible, powerful: The promise and peril of semaglutide in India

Cheap, accessible, and powerful semaglutide is changing India’s weight-loss and diabetes landscape. But as prices crash and access expands, the risks also increase

As India's weight management market expands, misleading ads risk rises

A week before semaglutide's patent expiry, the CDSCO issued an advisory warning pharma companies against promoting prescription weight-loss drugs, banned by law

Govt to intensify surveillance, audits against unauthorised GLP-1 sales

Online pharmacies, drug wholesalers under scanner; non-compliance may lead penalties, license cancellations

Counting calories for weight loss? Experts explain why it may not work

Experts highlight the limits of calorie tracking and share practical, sustainable ways for long-term weight management

India gets cheap GLP-1 drugs: What you must know before trying it

India's 'cheap Ozempic moment' is here as semaglutide prices fall sharply, but doctors warn against misuse and stress careful evaluation before using these weight-loss injections

Govt intensifies checks on illegal sale, misuse of GLP-1 weight-loss drugs

As cheaper GLP-1 weight-loss drugs flood India after patent expiry, the government has intensified surveillance to curb illegal sales, misleading promotion, and unsafe use without medical supervision

DCGI intensifies crackdown on unauthorised sale of GLP-1 weight-loss drugs

To ensure ethical pharmaceutical practices in the supply chain of weight-loss drugs of the GLP-1 class, the Drugs Controller General of India (DCGI) has intensified its regulatory surveillance against the unauthorised sale and promotion of the medications. To this end, inspections and audits have been carried out at many online pharmacy warehouses, drug wholesalers and retailers to check for unauthorised sale and improper prescription. With the recent introduction of multiple generic variants of GLP-1-based weight-loss drugs in the Indian market, concerns have emerged regarding their on-demand availability through retail pharmacies, online platforms, wholesalers, and wellness clinics, health ministry officials said on Tuesday. These drugs, when used without proper medical supervision, may lead to serious adverse effects and related health risks. Taking cognisance of the situation, the DCGI, in collaboration with state regulators, has initiated a series of targeted actions to curb .

10 pharma firms launch semaglutide in India; Nomura sees ₹12k-cr mkt

Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations

Semaglutide generics may fuel rush for cosmetic weight loss, warn doctors

As semaglutide goes off patent, doctors warn of misuse by non-obese individuals amid rising demand driven by social media and lower-cost generics

Ozempic copies set to crash to $14 in India as generic GLP-1 era starts

Natco Pharma Ltd. plans to sell an injection for semaglutide, the active ingredient in both Ozempic and Wegovy - with prices starting from ₹1,290

Ozempic patent expiry to trigger boom in weight-loss drugs in India

India is the first major country after Canada where Novo is losing patent on semaglutide and will see an onslaught of generic versions

Ozempic patent expiry set to trigger weight-loss drug boom in India

India is the first major country after Canada where Novo is losing patent on semaglutide and will see an onslaught of generic versions

Fat cells that burn energy could drive next wave of weight loss therapies

Body weight is biologically regulated, and targeting the right biological pathways can lead to meaningful weight loss that can help transform lives

What weight loss jabs reveal about science of appetite, hunger control

Originally developed for Type 2 diabetes, GLP-1 drugs like Ozempic and Wegovy prolong natural satiety signals, extending the post-meal fullness phase to support appetite control and weight loss

Ozempic and other weight-loss drugs: Cost, risks, who really needs them

As Ozempic and other GLP-1 drugs gain popularity, experts explain who qualifies, the real health benefits, potential risks, side effects, and why supervision is critical